News

Article

Clinical Quiz: Long-term Gout Management and Special Considerations from 2020 ACR Gout Guidelines

This clinical quiz, our last in a series of 4, focuses on recommendations for special populations and long-term management from the 2020 ACR gout guidelines.

HCPLive clinical quiz image. Credit: HCPLive

Gout is a growing public health burden that impacts approximately 4% of US adults, with a prevalence that has more than doubled from the 1960s and is expected to continue to rise in the coming decades.1,2

Gout requires careful management to maintain quality of life and there are many factors for rheumatologists to take into account when treating patients with gout and particular considerations for people with comorbidities, as gout is a chronic disease that must be monitored and managed long-term.

In 2020, the American College of Rheumatology (ACR) issued new guidance and recommendations for the management of gout. The 17-page document, which was the group's first new guideline on the topic since 2012, contained 42 recommendations, including 16 strong recommendations. In this clinical quiz, the third in a series of 4 based on the guideline, we test your knowledge on the management of gout flares.3

True or False: In patients with chronic kidney disease, febuxostat is preferred over allopurinol for ULT.


Check out other quizzes on the 2020 ACR gout guidelines:

Initiation and titration of urate-lowering therapy

Gout flare management

Clinical Quiz: Lifestyle and Comorbidities from 2020 ACR Gout Guidelines

References:

  1. National Kidney Foundation. Quick facts: Gout and chronic kidney disease. National Kidney Foundation. August 19, 2024. Accessed August 25, 2024. https://www.kidney.org/kidney-topics/quick-facts-gout-and-chronic-kidney-disease.
  2. GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2024;6(8):e507-e517. doi:10.1016/S2665-9913(24)00117-6
  3. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout [published correction appears in Arthritis Care Res (Hoboken). 2020 Aug;72(8):1187. doi: 10.1002/acr.24401] [published correction appears in Arthritis Care Res (Hoboken). 2021 Mar;73(3):458. doi: 10.1002/acr.24566]. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi:10.1002/acr.24180
Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
4 experts are featured in this series.
4 experts are featured in this series.
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.